-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The HOA hemoglobin variant was first described by Virgil Fairbanks in 1971
HOA hemoglobin variant HOA hemoglobin variant thrombosis management
A foreign expert team tried to clarify these issues by studying current characteristics, treatment strategies and follow-up events.
During the 10-year median follow-up, 23 (56%) patients reported one or more symptoms that were thought to be related to elevated Hct, and 10 (24%) patients recorded thrombosis
In summary, the current research does not imply that Hgb/Hct levels are the main contributor to the incidence of HOA hemoglobinopathies-associated polycythemia, and indicates that the value of bloodletting therapy is limited
The current research does not imply that Hgb/Hct levels are the main contributor to the incidence of HOA hemoglobinopathies-associated polycythemia, and indicates that the value of bloodletting therapy is limited
Original source:
Original source:Gangat N, Oliveira JL, Hoyer JD, Patnaik MM, Pardanani A, Tefferi A.
Gangat N, Oliveira JL, Hoyer JD, Patnaik MM, Pardanani A, Tefferi A.
High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: clinical outcomes and impact of therapy in 41 cases.
Am J Hematol.
2021 Oct 11.
doi: 10.
1002/ ajh.
26375.
Epub ahead of print.
PMID: 34633117.
Leave a message here